Rapamycin Guide – mTOR, Dosing, and Evidence
Rapamycin is the rare drug that shows up in geroscience research consistently enough that serious longevity researchers take notice. It extends lifespan in mice more reliably than almost anything else we’ve tested. It also suppresses your immune system, can raise blood glucose, and interacts with CBD in ways that most people using both have no idea about.
This rapamycin guide covers what the evidence actually shows, where the gaps are, and what you need to think through before getting anywhere near a prescription.
What Is Rapamycin – The mTOR Pathway and Cellular Aging
Rapamycin was discovered in 1972 in soil samples from Easter Island (Rapa Nui, hence the name). Researchers were looking for antifungal compounds. They found one, but its initial medical application was as an immunosuppressant for organ transplant patients, marketed as Rapamune. The longevity angle came much later.
The mechanism runs through a protein called mTOR, short for mechanistic target of rapamycin. mTOR is essentially your body’s nutrient sensor. When amino acids, glucose, and growth factors are abundant, mTOR tells cells to grow, build protein, and divide. When nutrients are scarce, mTOR quiets down and autophagy activates instead. Cells clean up damaged components and recycle them.
As you age, mTOR activity tends to stay elevated even when it shouldn’t be. Cells keep receiving growth signals when what they need is maintenance. Rapamycin inhibits mTOR, which pauses that runaway growth signal and gives autophagy a window to operate.
mTORC1 vs mTORC2 – Why the Distinction Drives Everything
mTOR doesn’t operate as a single entity. It forms two distinct complexes with different functions and different sensitivities to rapamycin.
mTORC1 handles protein synthesis, cell growth, and suppression of autophagy. It responds acutely to rapamycin. Inhibit mTORC1 intermittently, and you periodically take the foot off the growth pedal, which lets autophagy run. This is the target for longevity applications.
mTORC2 regulates metabolic function, insulin signaling, and immune cell behavior. It is relatively resistant to rapamycin, but “relatively” matters here. With continuous dosing or high doses over time, rapamycin does begin to inhibit mTORC2. That’s where the metabolic problems come from: glucose intolerance, dyslipidemia, and insulin resistance. These aren’t speculative risks. They’re well-documented consequences of the mTORC2 inhibition that happens when rapamycin is used continuously.
This is why the dosing strategy matters so much. The intermittent, low-dose approach used in longevity contexts is designed specifically to keep mTORC1 inhibition selective. You hit mTORC1, let mTORC2 recover between doses, and avoid the sustained metabolic disruption. Whether that theoretical advantage fully plays out in humans is a different question, and the data is still catching up.
What the Evidence Actually Shows
The animal data is genuinely strong. Studies in mice have shown lifespan extension ranging from about 15% to 36% depending on sex, strain, and timing of initiation. Notably, late-onset dosing (starting in mice equivalent to middle-aged humans) still produced significant effects, and intermittent administration worked in both males and females. That late-onset result matters because it suggests the window for intervention may not be limited to early life.
Human data is thinner, and you should know what it actually found rather than what gets reported in headlines.
The PEARL trial (results published 2024) studied 48 weeks of compounded rapamycin in healthy postmenopausal women at 5mg or 10mg once weekly. The primary outcome (visceral adiposity) was not significantly different from placebo in either group. The 10mg group showed roughly a 6% increase in lean mass and self-reported improvements, but the trial was not powered to make causal claims on secondary outcomes.
A 2014 study by Mannick and colleagues tested everolimus (a rapamycin analog) at 5mg weekly for six weeks in older adults before flu vaccination. The result was roughly a 20% increase in vaccine titer response and a reduction in exhausted T cells, with no increase in infection risk during the study period. This is one of the better human data points for immune function specifically.
One more: a trial examining rapamycin in women undergoing IVF found that 1mg daily for 21 to 28 days before oocyte retrieval was associated with more than triple the clinical pregnancy rates compared to controls. Small trial, specific population, needs replication, but the reproductive biology angle is real.
Bottom line: the animal evidence is compelling. Human evidence is early and scattered. Anyone presenting this as settled science is ahead of the data.
Longevity Dosing – What to Know If You’re Considering It
Transplant dosing and longevity dosing are not the same thing, and conflating them is how people get into trouble. Transplant patients take rapamycin daily at doses of 1mg or more to sustain continuous immunosuppression. That’s a fundamentally different context from what longevity researchers are studying.
The framework commonly cited in longevity circles is roughly 0.075 to 0.15 mg/kg once weekly, which works out to approximately 5 to 10mg per week for a 70kg adult. That range appears repeatedly in physician discussions and in trials like PEARL. This is not a dosage recommendation, and you should not use it to self-prescribe. What it tells you is that the approach involves weekly dosing at doses meaningful enough to require a prescription and medical oversight.
One practical point on compounded rapamycin: formulations have bioavailability roughly 3 to 3.5 times lower than standard generic tablets, so the labeled dose doesn’t translate directly. Physicians in this space account for this; it’s why numbers vary across sources.
The other thing worth stating plainly: rapamycin doesn’t replace the basics. Exercise, sleep, and nutrition aren’t just complementary to longevity biology, they operate through many of the same pathways. Fasting and caloric restriction inhibit mTOR. Zone 2 cardio activates autophagy. If those aren’t already part of your life, the marginal benefit of adding a prescription drug with real side effects is not a good trade.
Risks and Side Effects
The metabolic effects are underreported in biohacker circles, so let’s be direct about them.
Glucose intolerance and insulin resistance are documented consequences of mTOR inhibition, particularly with continuous use. mTORC2 inhibition over time disrupts insulin signaling downstream. Elevated blood glucose is a real finding in rapamycin users, not a theoretical concern.
Hyperlipidemia is also documented, with elevated triglycerides and LDL observed in both transplant patients and some longevity users.
Immunosuppression is the mechanism that made the drug useful for transplant patients, and the reason it carries infection risk and impaired wound healing. Intermittent dosing may attenuate these effects but doesn’t eliminate them.
The CBD interaction is a real safety issue. Rapamycin is metabolized by CYP3A. CBD is a potent CYP3A inhibitor that slows rapamycin clearance, raising circulating levels well beyond what the dose alone would predict. Anyone using both is potentially getting substantially more rapamycin than intended. This interaction is widely missed in biohacker communities.
Women-specific effects deserve more than a footnote. Menstrual irregularities and ovarian dysfunction have been observed with rapamycin use, which is not surprising given mTOR’s role in ovarian function. The IVF data showing potential benefit at low doses adds a layer of complexity rather than resolving it. Women of reproductive age considering rapamycin need specific discussion with a physician about timing, dosing, and monitoring, not just the standard male-skewed longevity framework.
The autophagy-cancer relationship cuts both ways. Autophagy suppression is associated with tumor initiation, so restoring autophagy via mTOR inhibition may reduce early cancer risk. But established tumors can also exploit autophagy for survival under nutrient stress. Whether rapamycin is protective or permissive for cancer depends heavily on context. There is no clean answer here.
Bryan Johnson eventually discontinued rapamycin, citing elevated blood glucose, increased susceptibility to infections, and impaired healing. His experience doesn’t settle the science, but it demonstrates these effects are real and show up in highly optimized individuals. In his case, they outweighed the theoretical longevity benefit.
Who Should Actually Consider This
The honest case for rapamycin is narrow: over 40, solid baseline metrics, sleep and exercise and nutrition genuinely optimized, physician willing to monitor, and a specific reason to think mTOR modulation matters. That constellation is uncommon.
Who should skip it:
- Healthy people under 40 with no specific health concerns. The risk-benefit math doesn’t favor experimentation here.
- Anyone already immunocompromised for any reason.
- Anyone pregnant or actively trying to conceive.
- Anyone taking CBD regularly without understanding the CYP3A interaction.
The longevity clinic space varies widely. Some have meaningful oversight and bloodwork protocols. Others sell prescriptions with minimal follow-up. Rapamycin requires real monitoring, not a telehealth subscription.
Natural mTOR Inhibition
Rapamycin inhibits mTOR directly, but the same pathway responds to things that don’t require a prescription. Intermittent fasting, extended caloric restriction, and fasted cardio all reduce mTOR activity and trigger autophagy. These are meaningful interventions, not consolation prizes. If the biology of mTOR and autophagy interests you, the lifestyle fundamentals are where to start. They have decades of evidence, no prescription, and a side effect profile that improves rather than degrades your metabolic health.
FAQ
What’s the difference between rapamycin and rapalogs like everolimus?
Rapalogs are structural analogs of rapamycin with modified pharmacokinetic profiles. Everolimus, for example, has a shorter half-life than rapamycin. Both inhibit mTOR through the same mechanism. The Mannick 2014 immune aging study used everolimus, not rapamycin itself, which matters when interpreting that data.
Can women take rapamycin?
Women can and do take rapamycin, but the risk-benefit picture is meaningfully different from men. Menstrual irregularities and ovarian effects are documented. The PEARL trial studied postmenopausal women specifically, so data in premenopausal women is limited. Women considering rapamycin need sex-specific medical guidance, not just a generic protocol.
Does rapamycin suppress or enhance immune function?
Both, depending on the context. It immunosuppresses at transplant doses and with continuous use. At low intermittent doses, the Mannick everolimus study suggests potential immunomodulation in older adults, improving vaccine responses and reducing T cell exhaustion. These are not the same thing as general enhancement, and the mechanism is not fully worked out.
Is it safe long-term?
Nobody knows. The transplant data tells us what happens with continuous high-dose use, and it’s not the same context. Long-term human data for low-dose intermittent use in healthy people simply doesn’t exist yet. Asserting it’s safe long-term is not currently supported by evidence.
What about CBD or other CYP3A interactors?
CBD inhibits CYP3A4, the enzyme that metabolizes rapamycin. Combining them can significantly increase rapamycin exposure without any dose change. Other CYP3A interactors include grapefruit juice, some antifungals, and several common medications. Tell your physician about everything you’re taking before starting rapamycin.
Can I just take it and skip the fundamentals?
No. The same pathways rapamycin targets are activated by exercise, fasting, and sleep. If those aren’t in place, you’re reaching for a prescription drug with real risk to compensate for recoverable lifestyle gaps. That’s not good risk management, and any physician doing this properly will tell you the same.